Evidence map›Paper›PMID 42245722›Full record

ReviewFrontiers in oncology2026

Carcinoma of unknown primary (CUP) of the head and neck: state of the art and future perspectives.

Sara Farinatti, Alberto Paderno, Caterina Giannitto, Cristina Gurizzan, Silvia Uccella, Luigi Lorini, Maria Ausilia Teriaca, Fabio Ferreli, Marcello Rodari, Carlo Resteghini and 4 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sara FarinattiMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Alberto PadernoDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Caterina GiannittoRadiology Division, IRCCS Humanitas Research Hospital, Milan, Italy.
Cristina GurizzanMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Silvia UccellaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Luigi LoriniMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Maria Ausilia TeriacaDepartment of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Milan, Italy.
Fabio FerreliDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Marcello RodariDepartment of Nuclear Medicine, IRCCS Humanitas Research Hospital, Milan, Italy.
Carlo ResteghiniMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Armando Di BelloMedical Oncology, Università Cattolica del Sacro Cuore, Comprehensive Cancer Center, Fondazione Policlinico Gemelli, IRCCS, Rome, Italy.
Giuseppe MercanteDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Giuseppe SprianoDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Paolo BossiMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in molecular oncology, head and neck cancer diagnosis still relies on anatomical site and histopathology. In up to 5% of metastatic cases, no identifiable primary tumor is found, defining carcinoma of unknown primary (CUP) and posing significant diagnostic and therapeutic challenges. We conducted a narrative review of the literature focusing on current diagnostic and treatment strategies for head and neck CUP, including imaging, viral biomarkers (HPV, EBV), minimally invasive procedures, and transoral robotic surgery (TORS). While TORS plays a dual role in diagnosis and treatment, a multidisciplinary approach of neck dissection, radiotherapy, and chemotherapy in high-risk patients, remains the cornerstone of management. Personalization is increasingly crucial in this comprehensive context, mainly involving treatment tailoring and radiotherapy planning, where limited evidence on field definition is available. Ongoing trials, such as UK FIND study, highlight the potential of targeted surgery to tailor and possibly reduce radiotherapy fields for better patient outcomes and improved quality of life.

Indexed as

carcinoma of unknown primaryhead and neck cancerpersonalizationsquamous cell carcinomastrans oral robotic surgery

Identifiers

PMID42245722
PMCPMC13229717

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.